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Abstract
Background: It has been reported that Chlamydophila (C.) pneumoniae is involved in the initiation
and promotion of asthma and chronic obstructive pulmonary diseases (COPD). Surprisingly, the
effect of C. pneumoniae on airway function has never been investigated.
Methods: In this study, mice were inoculated intranasally with C. pneumoniae (strain AR39) on day
0 and experiments were performed on day 2, 7, 14 and 21.
Results: We found that from day 7, C. pneumoniae infection causes both a sustained airway
hyperresponsiveness and an inflammation. Interferon-γ (IFN-γ) and macrophage inflammatory
chemokine-2 (MIP-2) levels in bronchoalveolar lavage (BAL)-fluid were increased on all
experimental days with exception of day 7 where MIP-2 concentrations dropped to control levels.
In contrast, tumor necrosis factor-α (TNF-α) levels were only increased on day 7. From day 7 to
21 epithelial damage and secretory cell hypertrophy was observed. It is suggested that, the
inflammatory cells/mediators, the epithelial damage and secretory cell hypertrophy contribute to
initiation of airway hyperresponsiveness.
Conclusion: Our study demonstrates for the first time that C. pneumoniae infection can modify
bronchial responsiveness. This has clinical implications, since additional changes in airway
responsiveness and inflammation-status induced by this bacterium may worsen and/or provoke
breathlessness in asthma and COPD.
Introduction
The association between respiratory infections and
asthma exacerbations has been evaluated both for viral
agents [1-3], and non-viral respiratory pathogens, such as
Mycoplasma pneumoniae and Chlamydophila pneumoniae [4-
8]. Involvement of C. pneumoniae in the initiation and
promotion of asthma and COPD has been suggested [9-
12].
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unique growth cycle involving infectious elementary bod-
ies and replicative reticulate bodies [13,14]. Epithelial
cells appear to be the primary targets for infection by C.
pneumoniae, although macrophages are also infected
[15,16].
Mice are susceptible to C. pneumoniae infections by intra-
nasal inoculation [17] and develop pneumonia with char-
acteristics resembling those of human disease [15,18,19].
C. pneumoniae can be isolated from tissues and peripheral
blood mononuclear cells, and specific DNA can be
detected in the same sites by PCR [20] and by immunohis-
tochemistry [17,21].
The effect of this bacterium on airway responsiveness has
not yet been investigated. Inoculation of M. pneumoniae in
hamsters increases airway hyperresponsiveness to hista-
mine [22], and M. pneumoniae inoculation in allergen-sen-
sitized mice modulates airway hyperresponsiveness and
lung inflammation [23].
C. pneumoniae infection in monocytes in vitro induces
TNF-α secretion [19] and activates nuclear factor-κB (NF-
κB) [24]. The activity of NF-κB is highly correlated to the
degree of lung dysfunction and to the course of the disease
in an animal model of asthma [25].
A recent multicenter, double-blind, randomized, placebo-
controlled clinical study assessed oral telithromycin as a
supplement to standard of care treatment for adult
patients with acute exacerbations of asthma [26]. Ketolide
antibiotic treatment was associated with statistically sig-
nificant and clinically substantial benefits. In this popula-
tion 61% of patients had evidence of C. pneumoniae and/
or M. pneumoniae infection and the effect of telithromycin
on FEV1 was statistically significant in patients with docu-
mented infection at baseline and not in those patients
without evidence of infection. However, there were no dif-
ferences between infection-positive and -negative groups
in terms of the other study outcomes, so that the mecha-
nisms of benefit remain unclear.
The aim of our study was to evaluate the effect of C. pneu-
moniae infection on airway function in mice and to find
possible relations with inflammatory cells and/or media-




Male BALB/c mice of 5–6 weeks of age were obtained from
the Central Animal Laboratory at Utrecht University, The
Netherlands. They were housed under controlled condi-
tion in macrolon cages containing 8 mice per cage. Water
and standard chow were presented ad libitum. Animal
care and use were performed in accordance with the
guidelines and approval of the Dutch Committee of ani-
mal experiments.
Treatment
Mice were anaesthetized with a short lasting inhalation
anesthetic (Halothane) and inoculated intranasally with
C. pneumoniae strain AR39 in saline (50 µl, 106 inclusion-
forming units (IFU)) at day 0. Tests were performed at
days 2, 7, 14 and 21. Control animals were treated in the
same way with saline.
Airway responsiveness in conscious unrestrained mice
Airway responsiveness was measured in vivo at day 2, 7, 14
and 21 from the infection using a whole body plethysmo-
graph (Buxco, Sharon, CT, USA) [27]. The plethysmo-
graph consisted of a reference chamber and an animal
chamber. The animal chamber was attached to the outside
via a pneumotachograph in the top of the plethysmo-
graph. An aerosol inlet to the animal chamber was centri-
cally located in the roof of the animal chamber. When an
animal was placed in the animal chamber and was breath-
ing quietly, pressure fluctuated within that chamber.
These changes in box pressure represented the difference
between tidal volume and thoracic movement during res-
piration. The differential pressure transducer measured
the changes in pressure between the animal chamber and
the reference chamber and brings these data to a pream-
plifier. Thereafter, data were sent to a computer where sev-
eral parameters were calculated, representing the lung
function of the animal. In the present study, mice were
exposed for 3 minutes to doubling doses of aerosolized
metacholine ranging from 1.56 mg/ml to 25 mg/ml. After
exposure to metacholine lung function was measured for
3 minutes. From the known lung function parameters
peak expiratory flow (PEF), tidal volume (TV), expiratory
time (Te) and frequency (f), the computer calculates the
enhanced pause (PenH).
BAL and differential cell counts
Broncho-alveolar lavage (BAL) was performed in the same
animals that were used for in vivo airway hyperresponsive-
ness measurements [27]. Mice were killed by cervical dis-
location 2, 7, 14, 21 days after inoculation. The trachea
was trimmed free of connective tissue and the upper part
was removed for histology (see below). In the lower part
of the trachea a cannula was inserted. The lungs were filled
with 1 ml aliquots of pyrogen free saline (0.9% NaCl)
supplemented with aprotenine in 5% bovine serum albu-
min of 37°C in situ. Fluid was collected in a plastic tube
on ice (4°C) (totally 1 ml). This procedure was repeated 3
times with aliquots of pyrogen free saline (0.9% NaCl)
and fluid was collected in a separate plastic tube on ice
(4°C) and the cell suspensions recovered from each ani-Page 2 of 9
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were centrifuged (400 g, 4°C, 5 min) and the supernatant
from the 1 ml aliquots were collected and stored at -30°C
till IFNγ, MIP-2 and TNF-α were measured by ELISA. The
pellets from the 1 ml and 3 ml aliquots were pooled and
re-suspended in totally 150 µl PBS (4°C). The total
number of BAL cells was counted by use of a Bürker-Türk
chamber. For differential BAL cell counts cytospin prepa-
rations were made and stained with Diff-Quick (Merz &
Dade A.G., Düdingen, Switzerland). Cells were differenti-
ated into macrophages, lymphocytes, neutrophils and
eosinophils by standard morphology. At least 200 cells
per cytospin preparation were counted and the absolute
number of each cell type was calculated.
INF-γ, MIP-2, and TNF-α ELISA
INF-γ, MIP-2, and TNF-α were analysed as previously
reported [28-30]. Flat-bottom microplates (96-wells,
Maxisorp, Nunc, Life Technologies, Breda, The Nether-
lands) were coated for over night at 4°C with capture anti-
body (100 µl per well) purified Rt α Ms IFNγ, purified Rt
α Ms MIP-2, purified Rt α Ms TNF-α (BioSource Interna-
tional, Inc., Camarillo, USA). After coating, plates were
washed with PBS containing 0.05% Tween-20, and
blocked with ELISA-buffer (2 mM EDTA, 136.9 mM NaCl,
50 mM Tris, 0.5% BSA and 0.05% Tween-20, pH 7.2) at
room temperature (RT) for 1 hour while gently shaking.
After removing the ELISA buffer, 100 µl of samples and
standards (rmIFNγ, rmMIP-2, or rmTNF-α (BioSource)
were applied and incubation was continued at RT for 2
hours. Thereafter, the second antibody diluted in ELISA-
buffer was added followed by incubation at RT for 2 hours
while shaking. After washing, 100 µl anti-DIG-POD (anti-
Digoxigenin conjugated with horse-radish peroxidase)
(Roche Diagnostics) was applied and incubation was con-
tinued at RT for 1 hour. After washing, streptavidin-perox-
idase (0.1 µg/ml, CLB) was added and incubation was
performed at RT for 1 hour. After washing the plates, 0.4
mg/ml o-phenylenediamine-dihydrochloride in PBS con-
taining 0.04% hydrogen peroxide was added. After
approximately 5 minutes the reaction was stopped by
adding 4 M H2SO4. Subsequently, optical density was
measured at 492 nm.
Preparation of specimens for scanning electron 
microscopy observation
At day 2, 7, 14, 21 tracheas were removed, gently washed
in 0.9% saline solution and immediately fixed in 4% for-
maldehyde fixative [31]. After fixation, they were opened
longitudinally and dehydrated in increasing alcohol
series. A Critical Point drying (Balzers CPD 030) was per-
formed and finally specimens were mounted on alumi-
num stubs with carbon double-sided adhesive tape and
sputter-coated with 200 Angstrom of gold (Baltec SCD
005). Samples were examined under scanning electron
microscopy (Philips 505).
Statistical analysis
Data are represented as mean (± standard error [SEM]).
Differences between groups were compared using an
unpaired, two-tailed Student's t-test. A p value < 0.05 was
considered significant. Each group consists of ≥7 animals.
Results
Airway responsiveness
The in vivo airway responsiveness following increasing
concentrations of aerosolized methacholine in spontane-
ously breathing mice was measured by using a barometric
plethysmograph (PenH).
Basal PenH values did not differ between the experimen-
tal groups (Day 2–21, Fig 1). At day 2, exposure to saline
nebulization slightly increased PenH in both experimen-
tal groups (Fig 1A). Moreover, metacholine concentra-
tion-dependently increased PenH and, again, there was
no difference between saline- and C. pneumoniae-treated
animals. Interestingly, on day 7 airway responsiveness
was significantly increased in the C. pneumoniae – com-
pared to the saline-treated group. At every concentration
of metacholine, the PenH was almost doubled (Fig 1B).
Similar results were obtained on day 14 (Fig 1C). On day
21 the airway hyperresponsiveness in C. pneumoniae-
treated animals fainted and significant changes were only
observed at lower concentration of methacholine (Fig
1D). These data indicate that C. pneumoniae infection
induces a sustained airway hyperresponsiveness.
Airway inflammation
To assess whether C. pneumoniae infection induces a
change of the inflammatory cell numbers in the lungs, the
total number of cells and the absolute number of macro-
phages, neutrophils and lymphocytes were counted in the
bronchoalveolar lavage fluid. There were no eosinophils
in the BAL-fluid of the experimental groups (Day 2–21).
Two days after the inoculation there was no difference
between the experimental groups with respect to total cell
numbers, however, there was a slight but significant
increase in the number of neutrophils in the C. pneumo-
niae-group (Fig 2A). There was a prominent inflammation
on day 7 and all the different cell types were increased in
the C. pneumoniae-group (Fig 2B). The inflammation was
slightly less 14 days after infection but still a significant
increase in macrophages and neutrophils was observed in
the C. pneumoniae-group (Fig. 2C). Comparable results
were obtained on day 21, however now there was a signif-
icant increase in the number of lymphocytes and the
increase in neutrophils was comparable with day 2 (Fig 2A
&2D).Page 3 of 9
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Several cytokines were measured in the BAL fluid to find a
possible relation between activation and influx of cells.
Since basal levels of cytokines did not differ between the
experimental days, the saline treated groups were pooled.
In C. pneumoniae-treated animals, the IFN-γ levels signifi-
cantly increased to more than 100 pg/ml throughout the
study (Fig 3A). On day 2, 14 & 21 MIP-2 concentrations
were 40% enhanced in C. pneumoniae-treated animals
compared to the control group. On day 7 however, MIP-2
levels dropped to control levels and were significantly
decreased compared with day 2 (Fig 3B).
Interestingly, TNF-α was increased on day 7 (compared
both to the control group and day 2 after C. pneumoniae),
after which the concentrations dropped to control levels
on day 14 and 21 (Fig. 3C).
Scanning electron microscopy
All samples obtained from saline-treated animals showed
no alterations of ciliated or secretory cells (Fig. 4E). In
contrast, the respiratory epithelium of mice infected with
C. pneumoniae after 2 days showed hyperthrophic goblet
cells and some scattered bacteria that were observed pre-
dominantly in contact with ciliated cells (Fig. 4A). After 7
days ciliary disorientation was the most evident change,
hyperplasia and hypertrophia of the secretory cells were
noticeable and there were a few single chlamydial bodies
(Fig. 4B). Detached cells were observed only occasionally.
The most relevant alterations were seen 14 days after
infection: the epithelium appeared severely damaged,
goblet cells were notably hypertrophic and numerous bac-
teria were visible, also in little micro-colonies (Fig. 4C).
After 21 days a mucus component was present and the
normal architecture of the respiratory epithelium was lost
Airway responsiveness to increasing concentrations of methacholine at various points after inoculation of mice with saline (open bar ) r C. pneum n ae (black bars)F gure 1
Airway responsiveness to increasing concentrations of methacholine at various points after inoculation of mice with saline 
(open bars) or C. pneumoniae (black bars). A: Day 2; B: Day 7; C: Day 14, D: Day 21. (*p < 0.05; **p < 0.001; ***p < 0.005, n = 
7–8). Unrestrained plethysmograph measurements were performed for 3 min after each exposure to methacholine and 
expressed as Penh-values.Page 4 of 9
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Number of bronchoalveolar cells obtained by lung lavage at various points after inoculation of mice with saline (open bars) or C. pneum niae (black bars)Figur  2
Number of bronchoalveolar cells obtained by lung lavage at various points after inoculation of mice with saline (open bars) or 
C. pneumoniae (black bars). A: Day 2; B: Day 7; C: Day 14, D: Day 21. (*p < 0.05; **p < 0.005; ***p < 0.0001, n = 7–8).
Concentrations of: A IFN-γ (pg/ml) B MIP-2 (pg/ml) C TNF-α (pg/ml) in the bronchoalveolar lavage fluid 2, 7, 14, and 21 days after C. pneumoniae infection of iceFigure 3
Concentrations of: A IFN-γ (pg/ml) B MIP-2 (pg/ml) C TNF-α (pg/ml) in the bronchoalveolar lavage fluid 2, 7, 14, and 21 days 
after C. pneumoniae infection of mice. Data are presented as mean ± SEM, n = 7–8. P < 0.005 ***, p < 0.0001 compared to the 
saline groups. #p < 0.01 compared to the C. pneumoniae group on day 2.
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Scanning electron microscopy of the epithelial layer of the trachea from mice inoculated saline (E) or at various points after infection with C. pneumoniaeFigure 4
Scanning electron microscopy of the epithelial layer of the trachea from mice inoculated saline (E) or at various points after 
infection with C. pneumoniae: A: Day 2; B: Day 7; C: Day 14, D: Day 21 (2000–3000×). Two days after infection, the respira-
tory epithelium showed hyperthrophy of goblet cells and some scattered bacteria that were observed prevalently in contact 
with ciliated cells (Fig. 4A). After 7 days ciliary disorientation was the most evident change and there were a few single chlamy-
dial bodies (Fig. 4B). The epithelium appeared severely damaged on day 14, goblet cells were notably hypertrophic and numer-
ous bacteria were visible, also in little microcolonies (Fig. 4C). In addition to exfoliated epithelial cells on day 21 (Fig 4D), in 
some areas shorter cilia began to appear, a marker of ciliary regeneration.
Respiratory Research 2007, 8:83 http://respiratory-research.com/content/8/1/83(Fig. 4D); in addition to exfoliated epithelial cells, in
some areas shorter cilia began to appear, a marker of cili-
ary regeneration.
Conclusion
C. pneumoniae infection may be a cofactor in the patho-
genesis of airway diseases such as asthma and COPD
[11,32-34]. It has been suggested that acute infection with
C. pneumoniae is associated with new onset of asthma
[4,10], and C. pneumoniae and M. pneumoniae infections
are involved in acute exacerbations of asthma. Data on
chronic C. pneumoniae infection in COPD patients indi-
cate this agent as a plausible candidate for the modulation
of the natural history of chronic bronchitis and emphy-
sema [12,35-37].
Atypical pathogen persistent infection may participate in
airway inflammation. Chlamydial infection activates a
cytokine response including basic fibroblast growth factor
[38] by smooth muscle cells, and TNF-α secretion by
monocytes [39]. TNF-α production is induced by C. pneu-
moniae heat shock protein 60 (HSP60) [40] and is associ-
ated with neutrophil influx and endothelial and epithelial
expression of IL-1 and adhesion molecules [41,42].
HSP60 also induces matrix metalloproteinases (MMPs)
production by macrophages, particularly of MMP-9, an
enzyme are felt to be involved in the pathogenesis of
emphysema [42]. Moreover, an association was observed
between the anti-C. pneumoniae heat shock protein 10
antibodies and adult onset asthma [34].
However, no data have so far been obtained in demon-
strating a role for C. pneumoniae infection in the pathogen-
esis of airway hyperresponsiveness in vivo. In our study
we evaluated the effect of acute C. pneumoniae infection
on bronchial reactivity in mice. This model allowed the
direct evaluation over time of the effects of the infection
on epithelial damage, cellular influx and cytokines in the
airways in relation to bronchial response to metacholine
challenge. Based on the results obtained, a likely sequence
of events can be proposed. The inoculation of C. pneumo-
niae into the respiratory tract may trigger alveolar macro-
phages to produce IFN-γ and MIP-2. Both cytokines are
increased in the BAL-fluid as early as two days after inoc-
ulation and attract and activate immune cells in order to
eliminate the infection with the bacteria. The production
of MIP-2 on day 2 might explain the slight but significant
neutrophil influx. At the same time, C. pneumoniae,
actively infects cells with the goal of endocellular replica-
tion. Epithelial cells appear to be the primary targets,
although other studies have shown that macrophages are
also infected [21]. On the basis of scanning electron
microscopy findings, we observed that inoculation of C.
pneumoniae resulted in epithelial damage and secretory
cell hypertrophia. These lesions were present in the early
phase post-inoculation (day 2) and this might be
explained by bacterial penetration into the epithelial cells
and by mediators (such as reactive oxygen species) that
are released by macrophages during elimination of C.
pneumoniae [43]. Evidence of C. pneumoniae replication
was found on day 7. Similar results were obtained in a
recent study, in which replication C. pneumoniae was
measured in supernatants of individual lung suspensions
of mice in time and peaked at day 7 [17]. In addition to
the presence of chlamydial bodies in the epithelial layer
(Fig 4B), the inflammatory cell influx and the level of
TNF-α peaked on this day. It is likely that the increase in
TNF-α contributes to the huge neutrophil influx at this
time point since this cytokine is a potent chemoattractant
and activator for neutrophils. The obvious increase of
TNF-α on day 7 might be due to the release of C. pneumo-
niae that replicated in the epithelial cells. In contrast to
what was seen with TNF-α, MIP-2 levels dropped signifi-
cantly compared with day 2, and increased again on day
14 and 21. At the latter two time points, MIP-2 might be
responsible for the (less pronounced) increase in neu-
trophils, since TNF-α was hardly present. The reason for
the hypobolic synthesis pattern for MIP-2 is unclear.
The sustained increase in INF-γ is probably due to the par-
ticular life cycle of this bacterium. Following completion
of the replication stage, the reticulate bodies once again
mature into elementary bodies that are released after lyses
of the infected cell and may infect other cells. It is likely
that the afore mentioned process and the release of the
inflammatory mediators are responsible for the epithelial
damage observed up until day 21. Epithelial damage
increased over time and was associated with airway hyper-
responsiveness. However, when evidence of cellular
regeneration was observed (day 21), this coincided with a
drop in the degree of hyperresponsiveness. This suggests
that epithelial damage following C. pneumoniae inocula-
tion may at least partly be responsible for alterations in
airway responsiveness [43]. It is not likely that the airway
hyperresponsiveness is due to a C. pneumoniae-induced
change in histamine synthesis [17] or metabolism [22],
since the mice were exposed to a cholinergic agonist.
A further finding was that acute infection is followed by a
striking increase of cellular influx after 7 days that per-
sisted till day 21. Neutrophil influx starts at day 2, reach-
ing the peak at day 7 with a four-fold increase in the
number of macrophages. It has to be stressed that there
was no influx of eosinophils. Crimi et al., [44] suggested,
that the degree of hyperresponsiveness in asthma patients
may be correlated with factors other than eosinophil
inflammation. One of these additional factors could be
the immune- and inflammatory-mediators released by
other cells.Page 7 of 9
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Respiratory Research 2007, 8:83 http://respiratory-research.com/content/8/1/83In summary, our study provides the first evidence that C.
pneumoniae infection can modify bronchial responsive-
ness in mice. The induction of the airway hyperrespon-
siveness might be due to inflammation and
morphological changes of the epithelial layer. These
changes could be induced by the infection itself and by
the mediators released by the inflammatory cells (such as
cytokines and reactive oxygen species). The future chal-
lenge is to substantiate the clinical significance of these
results by investigating 1) C. pneumoniae infection in ani-
mal models for asthma and COPD (i.e. ovalbumin sensi-
tized and challenged mice and mice exposed to cigarette
smoke, respectively) and 2) anti-microbial therapy in
(subgroups) of asthma- [16,26] and COPD- [45] patients.
Competing interests
F. Blasi, S. Aliberti, L. Allegra, G. Piatti, P. Tarsia, JM Osse-
wade, V. Verweij, FP Nijkamp, and G Folkerts, all have no
personal financial support or are involved in organiza-
tions with financial interest in the subject matter, and
present no actual or potential competing interests.
Authors' contributions
FB conceived the study, participated in its design, coordi-
nation and drafted the manuscript, SA participated to the
design of the study and to electron microscopy studies, LA
participated in the study design and coordination, GP per-
formed scanning electron microscopy, PT participated in
the study design and in drafting the manuscript, JMO par-
ticipated in the animal studies and supplied Chlamydo-
phila pneumoniae strains, VV participated in the animal
studies, FPN participated in the study design and coordi-
nation, GF conceived the study, participated in its design,
coordination and drafted the manuscript.
All the authors read and approved the final manuscript.
Acknowledgements
We thank Anna Grugnetti, Samantha Galbiati and Barbara Dallari for their 
excellent technical assistance in performing animal studies and electron 
microscopy assays.
References
1. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs
L, Symington P, O'Toole S, Myint SH, Tyrrell DA, et al.: Community
study of role of viral infections in exacerbations of asthma in
9-11 year old children.  Bmj 1995, 310(6989):1225-1229.
2. Folkerts G, Busse WW, Nijkamp FP, Sorkness R, Gern JE: Virus-
induced airway hyperresponsiveness and asthma.  Am J Respir
Crit Care Med 1998, 157(6 Pt 1):1708-1720.
3. Folkerts G, Walzl G, Openshaw PJ: Do common childhood infec-
tions 'teach' the immune system not to be allergic?  Immunol
Today 2000, 21(3):118-120.
4. Hahn DL, Dodge RW, Golubjatnikov R: Association of Chlamydia
pneumoniae (strain TWAR) infection with wheezing, asth-
matic bronchitis, and adult-onset asthma.  Jama 1991,
266(2):225-230.
5. Emre U, Roblin PM, Gelling M, Dumornay W, Rao M, Hammerschlag
MR, Schachter J: The association of Chlamydia pneumoniae
infection and reactive airway disease in children.  Arch Pediatr
Adolesc Med 1994, 148(7):727-732.
6. File TM Jr., Tan JS, Plouffe JF: The role of atypical pathogens:
Mycoplasma pneumoniae, Chlamydia pneumoniae, and
Legionella pneumophila in respiratory infection.  Infect Dis Clin
North Am 1998, 12(3):569-92, vii.
7. Cunningham AF, Johnston SL, Julious SA, Lampe FC, Ward ME:
Chronic Chlamydia pneumoniae infection and asthma exac-
erbations in children.  Eur Respir J 1998, 11(2):345-349.
8. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion
BP, Gaydos CA, Martin RJ: Detection of Mycoplasma pneumo-
niae in the airways of adults with chronic asthma.  Am J Respir
Crit Care Med 1998, 158(3):998-1001.
9. Nagy A, Kozma GT, Keszei M, Treszl A, Falus A, Szalai C: The devel-
opment of asthma in children infected with Chlamydia pneu-
moniae is dependent on the modifying effect of mannose-
binding lectin.  J Allergy Clin Immunol 2003, 112(4):729-734.
10. Sirmatel F, Ustunsoy H, Sirmatel O, Akdemir I, Dikensoy O: The
relationship between Chlamydia pneumoniae seropositivity
and peripheral vascular diseases, acute myocardial infarction
and late-onset asthma.  Infection 2003, 31(5):367-368.
11. Clementsen P, Permin H, Norn S: Chlamydia pneumoniae infec-
tion and its role in asthma and chronic obstructive pulmo-
nary disease.  J Investig Allergol Clin Immunol 2002, 12(2):73-79.
12. Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S,
Allegra L: Chlamydia pneumoniae and chronic bronchitis:
association with severity and bacterial clearance following
treatment.  Thorax 2002, 57(8):672-676.
13. Hammerschlag MR: The intracellular life of chlamydiae.  Semin
Pediatr Infect Dis 2002, 13(4):239-248.
14. Leinonen M: Pathogenetic mechanisms and epidemiology of
Chlamydia pneumoniae.  Eur Heart J 1993, 14 Suppl K:57-61.
15. Pal S, Peterson EM, de La Maza LM: Role of Nramp1 deletion in
Chlamydia infection in mice.  Infect Immun 2000,
68(8):4831-4833.
16. Komura H, Matsushima H, Ouchi K, Shirai M, Nakazawa T, Furukawa
S: Effects of antiasthma drugs on the growth of Chlamydo-
phila pneumoniae in HEp-2 cells.  J Infect Chemother 2003,
9(2):160-164.
17. Burian K, Hegyesi H, Buzas E, Endresz V, Kis Z, Falus A, Gonczol E:
Chlamydophila (Chlamydia) pneumoniae induces histidine
decarboxylase production in the mouse lung.  Immunol Lett
2003, 89(2-3):229-236.
18. Yang ZP, Cummings PK, Patton DL, Kuo CC: Ultrastructural lung
pathology of experimental Chlamydia pneumoniae pneumo-
nitis in mice.  J Infect Dis 1994, 170(2):464-467.
19. Kaukoranta-Tolvanen SS, Laurila AL, Saikku P, Leinonen M, Liesirova
L, Laitinen K: Experimental infection of Chlamydia pneumo-
niae in mice.  Microb Pathog 1993, 15(4):293-302.
20. Blasi F, Boman J, Esposito G, Melissano G, Chiesa R, Cosentini R, Tar-
sia P, Tshomba Y, Betti M, Alessi M, Morelli N, Allegra L: Chlamydia
pneumoniae DNA detection in peripheral blood mononu-
clear cells is predictive of vascular infection.  J Infect Dis 1999,
180(6):2074-2076.
21. Meijer A, Roholl PJ, Gielis-Proper SK, Meulenberg YF, Ossewaarde
JM: Chlamydia pneumoniae in vitro and in vivo: a critical eval-
uation of in situ detection methods.  J Clin Pathol 2000,
53(12):904-910.
22. Tamaoki J, Araake M, Chiyotani A, Isono K, Nagai A: Airway hyper-
responsiveness to histamine in mycoplasmal infection: role
of histamine N-methyltransferase.  Eur J Pharmacol 1998, 347(2-
3):257-260.
23. Chu HW, Honour JM, Rawlinson CA, Harbeck RJ, Martin RJ: Effects
of respiratory Mycoplasma pneumoniae infection on aller-
gen-induced bronchial hyperresponsiveness and lung inflam-
mation in mice.  Infect Immun 2003, 71(3):1520-1526.
24. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A,
Gulba DC: Chlamydia pneumoniae infection of vascular
smooth muscle and endothelial cells activates NF-kappaB
and induces tissue factor and PAI-1 expression: a potential
link to accelerated arteriosclerosis.  Circulation 1999,
100(13):1369-1373.
25. Bureau F, Bonizzi G, Kirschvink N, Delhalle S, Desmecht D, Merville
MP, Bours V, Lekeux P: Correlation between nuclear factor-
kappaB activity in bronchial brushing samples and lung dys-
function in an animal model of asthma.  Am J Respir Crit Care Med
2000, 161(4 Pt 1):1314-1321.Page 8 of 9
(page number not for citation purposes)
Respiratory Research 2007, 8:83 http://respiratory-research.com/content/8/1/83Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
26. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB: The
effect of telithromycin in acute exacerbations of asthma.  N
Engl J Med 2006, 354(15):1589-1600.
27. Folkerts G, Vlieger JW, de Vries A, Faas S, van Der Linde H, Engels F,
de Jong JC, Verheyen FA, Van Heuven-Nolsen D, Nijkamp FP: Virus-
and bradykinin-induced airway hyperresponsiveness in
guinea pigs.  Am J Respir Crit Care Med 2000, 161(5):1666-1671.
28. Smit JJ, Van Loveren H, Hoekstra MO, Karimi K, Folkerts G, Nijkamp
FP: The Slc11a1 (Nramp1) gene controls efficacy of myco-
bacterial treatment of allergic asthma.  J Immunol 2003,
171(2):754-760.
29. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL,
Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE: A novel
peptide CXCR ligand derived from extracellular matrix deg-
radation during airway inflammation.  Nat Med 2006,
12(3):317-323.
30. Hofstra CL, Van Ark I, Hofman G, Nijkamp FP, Jardieu PM, Van Oost-
erhout AJ: Differential effects of endogenous and exogenous
interferon-gamma on immunoglobulin E, cellular infiltra-
tion, and airway responsiveness in a murine model of allergic
asthma.  Am J Respir Cell Mol Biol 1998, 19(5):826-835.
31. Folkerts G, Verheyen AK, Geuens GM, Folkerts HF, Nijkamp FP:
Virus-induced changes in airway responsiveness, morphol-
ogy, and histamine levels in guinea pigs.  Am Rev Respir Dis 1993,
147(6 Pt 1):1569-1577.
32. Esposito S, Blasi F, Arosio C, Fioravanti L, Fagetti L, Droghetti R, Tar-
sia P, Allegra L, Principi N: Importance of acute Mycoplasma
pneumoniae and Chlamydia pneumoniae infections in chil-
dren with wheezing.  Eur Respir J 2000, 16(6):1142-1146.
33. Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld AR,
Ruffin RE, Mullins PR, Dangain J, Cooper BC, David DB, Allegra L:
Trial of roxithromycin in subjects with asthma and serologi-
cal evidence of infection with Chlamydia pneumoniae.  Am J
Respir Crit Care Med 2001, 164(4):536-541.
34. Betsou F, Sueur JM, Orfila J: Anti-Chlamydia pneumoniae heat
shock protein 10 antibodies in asthmatic adults.  FEMS Immu-
nol Med Microbiol 2003, 35(2):107-111.
35. Seemungal TA, Wedzicha JA, MacCallum PK, Johnston SL, Lambert
PA: Chlamydia pneumoniae and COPD exacerbation.  Thorax
2002, 57(12):1087-8; author reply 1088-9.
36. Wu L, Skinner SJ, Lambie N, Vuletic JC, Blasi F, Black PN: Immuno-
histochemical staining for Chlamydia pneumoniae is
increased in lung tissue from subjects with chronic obstruc-
tive pulmonary disease.  Am J Respir Crit Care Med 2000, 162(3 Pt
1):1148-1151.
37. Lieberman D, Ben-Yaakov M, Lazarovich Z, Ohana B, Boldur I:
Chlamydia pneumoniae infection in acute exacerbations of
chronic obstructive pulmonary disease: analysis of 250 hospi-
talizations.  Eur J Clin Microbiol Infect Dis 2001, 20(10):698-704.
38. Rodel J, Woytas M, Groh A, Schmidt KH, Hartmann M, Lehmann M,
Straube E: Production of basic fibroblast growth factor and
interleukin 6 by human smooth muscle cells following infec-
tion with Chlamydia pneumoniae.  Infect Immun 2000,
68(6):3635-3641.
39. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori
K, Leinonen M: Growth of Chlamydia pneumoniae in cultured
human peripheral blood mononuclear cells and induction of
a cytokine response.  Microb Pathog 1996, 21(3):215-221.
40. Kol A, Sukhova GK, Lichtman AH, Libby P: Chlamydial heat shock
protein 60 localizes in human atheroma and regulates mac-
rophage tumor necrosis factor-alpha and matrix metallo-
proteinase expression.  Circulation 1998, 98(4):300-307.
41. Libby P, Sukhova G, Lee RT, Galis ZS: Cytokines regulate vascular
functions related to stability of the atherosclerotic plaque.  J
Cardiovasc Pharmacol 1995, 25 Suppl 2:S9-12.
42. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, Fit-
zGerald MX, O'Connor CM: Matrix metalloproteinase expres-
sion and production by alveolar macrophages in
emphysema.  Am J Respir Crit Care Med 1997, 156(1):240-247.
43. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in
health and disease of the respiratory system.  Physiol Rev 2004,
84(3):731-765.
44. Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V: Dis-
sociation between airway inflammation and airway hyperre-
sponsiveness in allergic asthma.  Am J Respir Crit Care Med 1998,
157(1):4-9.
45. Karnak D, Beder S: Treatment of Chlamydia pneumoniae
infection and chronic obstructive pulmonary disease.  Expert
Opin Pharmacother 2002, 3(10):1461-1470.Page 9 of 9
(page number not for citation purposes)
